ERR2598267
fetal · fetal
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- fetal
- cancer_type_detailed
- —
- subtype
- fetal
- cancer_type
- fetal
- subtype
- fetal
- sex
- fetal
- race
- fetal
- fetal_age_forebrain
- 24
- umap1_2d
- -2.353812488
- umap2_2d
- 4.948895361
- umap1_3d
- 1.166502132
- umap2_3d
- 0.998483983
- umap3_3d
- -0.132993192
- dataset
- fetal
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.400
- KRAS_SIGNALING_DN+0.360
- MYOGENESIS+0.280
- ALLOGRAFT_REJECTION+0.270
- COAGULATION+0.270
- COMPLEMENT+0.250
- INTERFERON_ALPHA_RESPONSE+0.250
- FATTY_ACID_METABOLISM+0.240
- PANCREAS_BETA_CELLS+0.240
- XENOBIOTIC_METABOLISM+0.240
Top 10 suppressed
- G2M_CHECKPOINT-0.600
- E2F_TARGETS-0.580
- MYC_TARGETS_V1-0.520
- WNT_BETA_CATENIN_SIGNALING-0.490
- MYC_TARGETS_V2-0.400
- NOTCH_SIGNALING-0.400
- MITOTIC_SPINDLE-0.360
- DNA_REPAIR-0.350
- TGF_BETA_SIGNALING-0.330
- UNFOLDED_PROTEIN_RESPONSE-0.330
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ERR2598329 | fetal | fetal | 0.973 |
| 2 | ERR2598281 | fetal | fetal | 0.957 |
| 3 | ERR2598335 | fetal | fetal | 0.914 |
| 4 | ERR2598280 | fetal | fetal | 0.906 |
| 5 | ERR2598269 | fetal | fetal | 0.898 |
| 6 | SRR1399092 | GTEX | — | 0.892 |
| 7 | ERR2598266 | fetal | fetal | 0.890 |
| 8 | TCGA-50-6597-01A-11R-1858-07 | — | cohortA1 | 0.875 |
| 9 | SRR1328919 | GTEX | — | 0.872 |
| 10 | SRR1430570 | GTEX | — | 0.871 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.400 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_DN | 0.360 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.280 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.270 | Idelalisib | — uncovered |
| COAGULATION | 0.270 | Binimetinib | — uncovered |
| COMPLEMENT | 0.250 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.250 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.240 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.240 | Cobimetinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.240 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.230 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.210 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.210 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.210 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.190 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.180 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.140 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.140 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.110 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.110 | Idelalisib | — uncovered |